Industry pumps a lot of time and resources into pushing back against activists who insist producers must stop using sub-therapeutic antibiotics. But is the strategy on target?
Let’s see? What would make a good topic for a column aimed at generating controversy? Assuming, of course, that controversy “sells.”
Which it does, by the way.
I’d argue that few issues would fit that model better than antibiotics.